(NASDAQ: QNRX) Quoin Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.
Quoin Pharmaceuticals's earnings in 2026 is -$15,804,655.On average, 5 Wall Street analysts forecast QNRX's earnings for 2026 to be -$378,824,707, with the lowest QNRX earnings forecast at -$464,601,579, and the highest QNRX earnings forecast at -$304,240,239. On average, 4 Wall Street analysts forecast QNRX's earnings for 2027 to be -$261,099,295, with the lowest QNRX earnings forecast at -$306,847,381, and the highest QNRX earnings forecast at -$208,792,321.
In 2028, QNRX is forecast to generate -$61,491,943 in earnings, with the lowest earnings forecast at -$158,372,842 and the highest earnings forecast at $43,084,130.